MHRA grants conditional marketing authorization for AbbVie’s Tepkinly to treat aggressive blood cancer

  • Post author:
  • Post category:uncategorized

AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) as a monotherapy for the treatment of adults with relapsed…

Continue ReadingMHRA grants conditional marketing authorization for AbbVie’s Tepkinly to treat aggressive blood cancer